[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-hepatitis-b-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-hepatitis-b-virus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100581713","gene-discovery-in-chb-patients-to-identify-unknown-pathways-that-lead-to-b-and-nk-cell-deregulation-100581713",false,"NCT06853886","Gene Discovery in CHB Patients to Identify Unknown Pathways That Lead to B and NK Cell Deregulation","LiNKeB2","Inclusion Criteria:\n\n* Male or female, age ≥18 years old\n* HBV infection or chronic HBV infection untreated or treated with a nucleoside or nucleotide analog\n* Willing and able to provide written informed consent\n* Affiliated with a social securityregimen\n\nHealthy volunteer must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n* Male or female, age between 18 and 80 years\n* Willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Co-infection with HCV, HIV or HDV (or HBV for healthy volunteer)\n* Acute hepatitis in the year preceding recruitment\n* Other liver diseases : alcohol, obesity (BMI\\>30), diabetes, metabolic syndrome (dyslipidemia and\u002For known hypertension) - Underlying immunological or cancerous diseases\n* Patient with a disability that prevents him\u002Fher from fully understanding the requirements of the trial - Patient under court protection, guardianship or curatorship\n* Pregnant or breast-feeding women.\n\nSecondary exclusion criteria:\n\n* A healthy volunteer whose vaccination status does not match that expected on the basis of serological results\n* Positive blood pregnancy test on inclusion\n* Positive HCV, HIV or HDV test in a patient\n* Positive HBV, HCV, HIV or HDV test in a healthy volunteer",true,"ALL","18 Years",{"count":20,"type":21},140,"ESTIMATED","INTERVENTIONAL",[24],"NA","Natural Killer (NK) and B cell immune responses occur during the early stages of infection and are essential to eradicate it. Yet, chronic hepatitis B (CHB) infection occurs because the antiviral immune response is insufficient. In both NK and B cell studies we will explore the genetic alterations that occur during the varied chronic stages of the disease. We believe that our findings will allow us to understand the molecular signature of NK and B cells in the context of HBV infection.",[27],"Chronic Hepatitis B Virus",[29,30,31,32],"HBV","NK celles","TLR9","B cells","RECRUITING","2026-05-19",{"date":36,"type":37},"2026-05-20","ACTUAL",{"date":39,"type":37},"2025-08-12",{"date":41,"type":21},"2028-10-01",{"name":43,"class":44},"University Hospital, Limoges","OTHER",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":69,"locationsCount":71},"100610722","phase-4-prospective-cohort-study-on-peg-ifn--2b-in-improving-clinical-cure-rate-of-pediatric-patients-with-chronic-hepatitis-b-100610722","NCT07231276","Prospective Cohort Study on PEG-IFN-α-2b in Improving Clinical Cure Rate of Pediatric Patients With Chronic Hepatitis B","Prospective Cohort Study on Pegylated Interferon Alfa-2b in Improving Clinical Cure Rate of Adolescent and Pediatric Patients With Chronic Hepatitis B Virus Infection","Inclusion Criteria:\n\n* Aged 3 years and above but under 18 years;\n* Positive for hepatitis B virus (HBV) DNA;\n* Positive for hepatitis B surface antigen (HBsAg) (above the lower limit of baseline detection or \\> 0.05 IU\u002Fml);\n* The subject and their guardian(s) understand the study and voluntarily sign the informed consent form (if the guardians are the subject's parents, both parents must sign jointly).\n\nExclusion Criteria:\n\n* Co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), or human immunodeficiency virus (HIV);\n* Having contraindications to pegylated interferon alfa-2b:\n\n  1. Decompensated hepatitis B cirrhosis;\n  2. Subjects with autoimmune liver disease, metabolic liver disease, alcoholic liver disease, malignant tumor, decompensated liver disease, or a history of organ transplantation;\n  3. Subjects with severe neurological or psychiatric diseases;\n  4. Subjects with severe thyroid dysfunction, antinuclear antibody hyperactivity, or other autoimmune diseases;\n  5. Subjects with diabetes mellitus with poor blood glucose control;\n  6. Subjects with retinal or fundus lesions;\n  7. Subjects with severe heart disease, coronary heart disease, or cerebrovascular disease;\n  8. Subjects with poorly controlled epilepsy;\n* Adolescent and pediatric subjects with severe renal dysfunction (e.g., creatinine \\> 1.5 × upper limit of normal \\[ULN\\]);\n* Subjects deemed unsuitable for enrollment by the investigator(s).","3 Years",{"count":55,"type":21},113,[57],"PHASE4","In this study, comparisons will be made between the treatment group (which will receive pegylated interferon alfa-2b treatment) and the observation group (which will receive no drug treatment or be treated with nucleos(t)ide analogs). The primary objectives are to address the following questions: compare the efficacy evaluation indicators (with clinical cure rate as the primary one) between the pegylated interferon alfa-2b treatment group and the observation group; assess whether pegylated interferon alfa-2b treatment improves the clinical cure rate in patients with chronic hepatitis B virus (HBV) infection aged 3 years and above but under 18 years (adolescents and children); and explore optimized antiviral treatment regimens for adolescents and children with chronic HBV infection. The secondary objectives are to address the following questions: compare the immune response characteristics between adolescents and children with chronic HBV infection who achieved functional cure after pegylated interferon alfa-2b treatment and those who did not; investigate the immune mechanism underlying the achievement of functional cure in adolescents and children with chronic HBV infection treated with pegylated interferon alfa-2b; and identify plasma markers associated with treatment efficacy for predicting therapeutic outcomes.",[29,27],[29,61],"chronic hepatitis B virus","NOT_YET_RECRUITING","2025-11-13",{"date":65,"type":37},"2025-11-17",{"date":67,"type":21},"2026-01-01",{"date":41,"type":21},{"name":70,"class":44},"Nanfang Hospital, Southern Medical University",1]